CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
What Does Index Level Tell Us summarizes the core takeaways from index readings, offering a straightforward lens to interpret trends and potential moves.
19,344 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
When billionaire Dalio just warned about AI hype, it sparked a wider discussion on valuations and risk. This guide ex...
Upstart has stunned the market with a renewed focus on AI-powered lending, but questions remain. This article breaks ...
Soccer's biggest tournament is moving to North America in 2026 with an expanded field and a booming betting market. T...
If you’re chasing steady income, the default move isn’t always the highest yield. This guide explains why a dividend ...
As HOFT releases its Q1 2027 earnings, investors should focus on revenue trends, margins, and demand signals. This gu...
Trading activity in the largest non-stablecoin crypto assets cooled to two-year lows as investors sit on the sideline...
JEPI has struggled to keep up with a rallying market in 2026, fueling debate over whether its income strategy still f...
A sudden pullback in a high-profile space stock captured headlines. This article breaks down the factors behind intui...
Two AI models weigh in on whether SpaceX’s high-profile IPO will boost or drag Bitcoin in the near term. The verdict ...
With his 80th birthday approaching, Trump orchestrates high-profile appearances and a major White House event to proj...
In a crowded low Earth orbit, the real gains come from keeping satellites alive and productive. This article explains...